PRF科技公司宣布了其候选药物PRF-110在扩展临床前研究中的最新数据,该研究直接将其与已获批准的行业标准疗法进行了头对头比较。
PRF科技公司宣布了其候选药物PRF-110在扩展临床前研究中的最新数据,该研究直接将其与已获批准的行业标准疗法进行了头对头比较。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.